Matterhorn Biosciences

Matterhorn is a biotechnology company dedicated to discovering cell therapies targeting the MR1 molecule. The company develops T-cell receptor therapies based on the recently discovered MR1-restricted T cells, which can recognize and kill tumors from various tissue origins. The company stated that since MR1 binds to small metabolite antigens that are highly specific to cancer cells and shared across liquid and solid tumors, it creates opportunities for pan-cancer targeting and off-the-shelf T-cell therapies.